CONSOLIDATED STATEMENTS OF CASH FLOWS € in Thousands, £ in Thousands, SFr in Thousands, RM in Thousands, $ in Thousands, $ in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss after equity in losses from unconsolidated affiliates	$ (19,889)	$ (1,148)	$ (14,752)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation and amortization	13,966	13,555	11,385
Non-cash impact of operating leases	2,738	2,136	1,985
Deferred income tax benefit	(4,698)	(4,464)	(1,541)
Stock-based compensation	16,004	18,263	9,490
Provision for credit losses on convertible note receivable	3,899	0	0
Change in fair value of contingent consideration	(1,641)	(1,607)	0
Equity in losses of unconsolidated affiliates	1,465	1,280	720
Accretion of discounts and issuance costs	36	60	3,090
Provision for credit losses	0	353	614
Other losses (gains)	1,759	1,266	(91)
Changes in operating assets and liabilities (net of effect of acquisitions):
Accounts receivable	(1,494)	2,193	(5,755)
Inventories	(13,981)	(14,905)	(5,409)
Lease receivables	(9,078)	(5,902)	(611)
Other assets	(1,887)	(4,329)	340
Accounts payable	1,428	662	(280)
Other liabilities	(10,440)	(1,166)	159
Net cash (used in) provided by operating activities	(21,813)	6,247	(656)
CASH FLOWS FROM INVESTING ACTIVITIES:
Promissory note receivable issuance	(4,700)	(9,000)	0
Convertible note receivable issuance	0	0	(6,650)
Purchase of minority interest	0	0	(450)
Purchases of property and equipment	(2,114)	(1,768)	(686)
Proceeds from disposition of property and equipment	0	412	10
Net cash used in investing activities	(35,770)	(35,001)	(126,597)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock	3,191	169,230	4,273
Payments for taxes related to shares withheld for employee taxes	(5,269)	(1,629)	(1,477)
Payment of stock issuance costs	0	(314)	(214)
Proceeds from issuance of preferred stock	0	0	122,000
Payments of related party debts	0	0	(1,140)
Borrowings on line of credit and other debts	0	7	613
Repayments of line of credit borrowings and other debts	(203)	(890)	(291)
Notes Payable	(4,770)	0	0
Net cash (used in) provided by financing activities	(7,051)	166,404	123,764
FOREIGN EXCHANGE EFFECT ON CASH AND CASH EQUIVALENTS	(2,322)	(410)	793
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(66,956)	137,240	(2,696)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	223,574	86,334	89,030
CASH AND CASH EQUIVALENTS, END OF YEAR	156,618	223,574	86,334
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Non-cash transfers of equipment between inventory and property and equipment, net	2,563	4,600	4,437
Non-cash conversion of preferred stock to common stock	0	0	122,000
Contingent Consideration For Acquisitions	3,860	4,034	0
Note Payable Issued In Acquisition	0	15,900	0
Indemnity Holdback For Acquisition	1,420	346	0
VetZ GmbH
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of scil, net of cash acquired	(28,956)	0	0
Biotech Laboratories U.S.A. LLC
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of scil, net of cash acquired	0	(16,250)	0
BiEsseA s.r.1.
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of scil, net of cash acquired	0	(4,513)	0
Lacuna Diagnostics, Inc.
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of scil, net of cash acquired	0	(3,882)	0
Scil Animal Care Company
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of scil, net of cash acquired	0	0	(104,401)
CVM
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of scil, net of cash acquired	$ 0	$ 0	$ (14,420)